New heat-tolerant COVID-19 vaccine readies for human trials
A new heat-tolerant COVID-19 vaccine has delivered strong preclinical results. The vaccine can remain stable for up to 30 days at around 37 °C (98 °F) and researchers are looking to begin human trials later this year.
One particular challenge in effectively distributing COVID-19 vaccines across the world is the need for most vaccines to be kept at cold temperatures. Pfizer and BioNTech’s mRNA vaccine, for example, famously requires ultra-cold storage between -80 ºC and -60 ºC (-112 ºF to ‑76 ºF) making delivery to remote communities profoundly difficult.
Recent research from Pfizer amended those temperature guidelines, finding normal freezer temperatures of between -25 °C to -15 °C (-13 °F to 5 °F) are safe for at least two weeks. But even then, cold storage supply lines still make it challenging to widely distribute the vaccine.
“A thermostable or ‘warm vaccine’ is critical for remote or resource-limited locations with extremely hot climates which lack reliable cold storage supply chains, including regional communities in Australia’s outback and the Indo-Pacific region,” says Rob Grenfell, from Australia’s national science agency, the CSIRO.
The new vaccine was developed by biotech startup Mynvax, in conjunction with the Indian Institute of Science. Reporting in the journal ACS Infectious Diseases, researchers found the vaccine produces robust neutralizing antibodies against SARS-CoV-2 in mouse and guinea pig models.
“Our data shows that all formulations of Mynvax tested result in antibodies capable of consistent and effective neutralization of the Alpha, Beta, Gamma and Delta SARS-CoV-2 variants of concern,” says S.S Vasan, co-author on the new study.
This heat-tolerant vaccine formulation was found to be impressively stable in warm temperatures. It is effective for a month at 37 °C (98 °F) temperatures and even remained stable for up to 90 minutes at boiling temperatures of 100 °C (212 °F).
These promising preclinical results pave the way for a human trial to kick off later this year. Researchers hope a heat-tolerant COVID-19 vaccine with efficacy against newer SARS-CoV-2 variants will help deliver vaccines to remote communities.
The new study was published in the journal ACS Infectious Diseases.
Please keep comments to less than 150 words. No abusive material or spam will be published.